- Home
- CUTR vs ENLV Comparison
CUTR vs ENLV Comparison
Compare CUTR & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUTR
- ENLV
- Stock Information
- Founded
- CUTR 1988
- ENLV 2005
- Country
- CUTR United States
- ENLV Israel
- Employees
- CUTR N/A
- ENLV N/A
- Industry
- CUTR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- CUTR Health Care
- ENLV Health Care
- Exchange
- CUTR Nasdaq
- ENLV Nasdaq
- Market Cap
- CUTR 30.5M
- ENLV 28.4M
- IPO Year
- CUTR 2004
- ENLV 1995
- Fundamental
- Price
- CUTR $0.71
- ENLV $1.36
- Analyst Decision
- CUTR Buy
- ENLV Strong Buy
- Analyst Count
- CUTR 4
- ENLV 2
- Target Price
- CUTR $5.33
- ENLV $9.50
- AVG Volume (30 Days)
- CUTR 391.6K
- ENLV 32.8K
- Earning Date
- CUTR 11-06-2024
- ENLV 11-07-2024
- Dividend Yield
- CUTR N/A
- ENLV N/A
- EPS Growth
- CUTR N/A
- ENLV N/A
- EPS
- CUTR N/A
- ENLV N/A
- Revenue
- CUTR $169,188,000.00
- ENLV N/A
- Revenue This Year
- CUTR N/A
- ENLV N/A
- Revenue Next Year
- CUTR $6.35
- ENLV N/A
- P/E Ratio
- CUTR N/A
- ENLV N/A
- Revenue Growth
- CUTR N/A
- ENLV N/A
- 52 Week Low
- CUTR $0.65
- ENLV $1.15
- 52 Week High
- CUTR $10.02
- ENLV $4.59
- Technical
- Relative Strength Index (RSI)
- CUTR 36.51
- ENLV 63.09
- Support Level
- CUTR $0.67
- ENLV $1.19
- Resistance Level
- CUTR $0.83
- ENLV $1.27
- Average True Range (ATR)
- CUTR 0.06
- ENLV 0.06
- MACD
- CUTR 0.02
- ENLV 0.02
- Stochastic Oscillator
- CUTR 11.36
- ENLV 100.00
About CUTR Cutera Inc.
Cutera Inc is a medical device company. It specializes in the design, development, manufacture, marketing and servicing of laser and other energy based aesthetics systems for practitioners internationally. Its products include enlighten, excel HR, excel V, Xeo and Trusculpt 3D among others. The company markets and sells its products under the trademarks such as Cutera, Acutip, Coolglide, Enlighten, Excel HR, Excel V, Genesis plus, Pico-genesis, Titan, Trusculpt, and Xeo among others. It derives the majority of its revenue from the United States geographic segment.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.